Propanc Biopharma (PPCB) Secures Up to $100M from Hexstone Capital to Build a Bitcoin-Focused Digital Asset Portfolio as PRP Cancer Therapy Moves Toward 2026 Human Trials

According to The Block, Propanc Biopharma, a US-listed biopharmaceutical company (Nasdaq: PPCB), has disclosed a financing arrangement totaling up to $100 million with Hexstone Capital, a family office active in Bitcoin, Ethereum, Solana, Dogecoin, and other digital assets. The deal signals growing capital mobility between biotech and crypto markets.

Structured as a private placement using convertible preferred stock, the arrangement includes an initial $1 million infusion and potential additions totaling up to $99 million over the coming year. The funds will expand Propanc’s digital asset portfolio and advance development of its flagship therapy PRP, which is due to begin first-in-human trials in 2026.

The company has not disclosed which digital assets it plans to acquire, leaving allocation details undisclosed. The financing supports Propanc’s strategy for portfolio diversification alongside progress toward the clinical milestones for its lead cancer program.

In trading, PPCB fell about 4% to below $1, with a cumulative decline of roughly 43% over the past month, underscoring investor caution amid biotech and crypto funding activity.